Abstract: Disclosed are autonomous vehicles that may autonomously navigate at least a portion of a route defined by a service request allocator. The autonomous vehicle may, at a certain portion of the route, request remote assistance. In response to the request, an operator may provide input to a console that indicates control positions for one or more vehicle controls such as steering position, brake position, and/or accelerator position. A command is sent to the autonomous vehicle indicating how the vehicle should proceed along the route. When the vehicle reaches a location where remote assistance is no longer required, the autonomous vehicle is released from manual control and may then continue executing the route under autonomous control.

Abstract: Disclosed are autonomous vehicles that may autonomously navigate at least a portion of a route defined by a service request allocator. The autonomous vehicle may, at a certain portion of the route, request remote assistance. In response to the request, an operator may provide input to a console that indicates control positions for one or more vehicle controls such as steering position, brake position, and/or accelerator position. A command is sent to the autonomous vehicle indicating how the vehicle should proceed along the route. When the vehicle reaches a location where remote assistance is no longer required, the autonomous vehicle is released from manual control and may then continue executing the route under autonomous control.

Abstract: This invention is directed to physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and pharmaceutically acceptable salts of the compounds of formula (I) and N-oxides thereof, Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmnaceutical compositions comprising compoundS of formula (I), their phatmaceUtical use and methods for their preparation.

Abstract: A system and method is provided for changing defined user interface elements in a previously compiled program using a user interface description file without modifying the compiled program. The method includes the operation of loading the user interface description file from a storage location accessible to the compiled program. The user interface description file can contain user interface definitions and is not linked into the compiled program. The user interface description file can also be parsed to enable the user interface description file to be sent to a configurable filter in communication with the compiled program. A further operation is validating the user interface description file using the configurable filter. An additional operation is defining the compiled program's user interfaces and the interaction between the user interfaces, the compiled program, and data structures for the compiled program based on the user interface description file.

Abstract: The invention includes a system and method for changing defined elements in a previously compiled program using a data structure description file without modifying the compiled program. The method can include the operation of loading a data structure description file from a storage location accessible to the compiled program. The data structure description file contains definitions of data structures and is not linked into the compiled program. Another operation is parsing the data structure description file into a configurable filter for the compiled program. The data structure description file can then be validated in the configurable filter. A further operation is defining the compiled program's data structures based on the definitions of the data structures in the data structure description file.

Abstract: This invention is directed to physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; R1 represents hydrogen or a straight- or branched-chain alkyl group of 1 to about 4 carbon atoms, optionally substituted by hydroxy or one or more halogen atoms, or when Z1 represents a direct bond R1 may also represent a lower alkenyl or lower alkynyl group, or a formyl group; R2 represents hydrogen, alkenyl, alkoxy, alkyl, alkylsulphinyl, alkylsulphonyl, alkylthio, aryl, arylalkyloxy, arylalkylsulphinyl, arylalkylsulphonyl, arylalkylthio, aryloxy, arylsulphinyl, arylsulphonyl, arylthio, cyano, cycloalkenyl, cycloalkenyloxy, cycloalkyl, cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy, hydroxy, —SO2NR4R5, —NR4SO2R5, —NR4R5, —C(?O)R5, —C(?O)C(?O)R5, —C(?O)NR4R5, —C(?O)OR5, —O(C?O)NR4R5, or

Abstract: This invention is directed to physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; R1 represents hydrogen or a straight- or branched-chain alkyl group of 1 to about 4 carbon atoms, optionally substituted by hydroxy or one or more halogen atoms, or when Z1 represents a direct bond R1 may also represent a lower alkenyl or lower alkynyl group, or a formyl group; R2 represents hydrogen, alkenyl, alkoxy, alkyl, alkylsulphinyl, alkylsulphonyl, alkylthio, aryl, arylalkyloxy, arylalkylsulphinyl, arylalkylsulphonyl, arylalkylthio, aryloxy, arylsulphinyl, arylsulphonyl, arylthio, cyano, cycloalkenyl, cycloalkenyloxy, cycloalkyl, cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy, hydroxy, —SO2NR4R5, —NR4SO2R5, —